<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31515300</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>2</Issue><PubDate><Year>2020</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Executive, language and fluency dysfunction are markers of localised TDP-43 cerebral pathology in non-demented ALS.</ArticleTitle><Pagination><StartPage>149</StartPage><EndPage>157</EndPage><MedlinePgn>149-157</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2019-320807</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Approximately 35% of patients with amyotrophic lateral sclerosis (ALS) exhibit mild cognitive deficits in executive functions, language and fluency, without dementia. The precise pathology of these extramotor symptoms has remained unknown. This study aimed to determine the pathological correlate of cognitive impairment in patients with non-demented ALS.</AbstractText><AbstractText Label="METHODS">In-depth neuropathological analysis of 27 patients with non-demented ALS who had undergone cognitive testing (Edinburgh Cognitive and Behaviour ALS Screen (ECAS)) during life. Analysis involved assessing 43&#x2009;kDa Tar-DNA binding protein (TDP-43) accumulation in brain regions specifically involved in executive functions, language functions and verbal fluency to ascertain whether functional deficits would relate to a specific regional distribution of pathology.</AbstractText><AbstractText Label="RESULTS">All patients with cognitive impairment had TDP-43 pathology in extramotor brain regions (positive predictive value of 100%). The ECAS also predicted TDP-43 pathology with 100% specificity in brain regions associated with executive, language and fluency domains. We also detected a subgroup with no cognitive dysfunction, despite having substantial TDP-43 pathology, so called mismatch cases.</AbstractText><AbstractText Label="CONCLUSIONS">Cognitive impairment as detected by the ECAS is a valid predictor of TDP-43 pathology in non-demented ALS. The profile of mild cognitive deficits specifically predicts regional cerebral involvement. These findings highlight the utility of the ECAS in accurately assessing the pathological burden of disease.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gregory</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-3337-4079</Identifier><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK jgregor2@ed.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDade</LastName><ForeName>Karina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bak</LastName><ForeName>Thomas H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Philosophy, Psychology and Language Science, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pal</LastName><ForeName>Suvankar</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chandran</LastName><ForeName>Siddharthan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Euan MacDonald Centre for Motor Neurone Disease Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Philosophy, Psychology and Language Science, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>G1100616</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L016400/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/L023784/2</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>doi: 10.1136/jnnp-2019-321940</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056344" MajorTopicYN="Y">Executive Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007806" MajorTopicYN="N">Language Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014705" MajorTopicYN="Y">Verbal Behavior</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">ECAS</Keyword><Keyword MajorTopicYN="N">Neuropathology</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">cognition</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31515300</ArticleId><ArticleId IdType="pmc">PMC6996101</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2019-320807</ArticleId><ArticleId IdType="pii">jnnp-2019-320807</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein LH, Abrahams S. Changes in cognition and behaviour in amyotrophic lateral sclerosis: nature of impairment and implications for assessment. Lancet Neurol 2013;12:368&#x2013;80. 10.1016/S1474-4422(13)70026-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(13)70026-7</ArticleId><ArticleId IdType="pubmed">23518330</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:153&#x2013;74. 10.1080/21678421.2016.1267768</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1267768</ArticleId><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Leigh PN, Harvey A, et al. . Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia 2000;38:734&#x2013;47. 10.1016/S0028-3932(99)00146-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0028-3932(99)00146-3</ArticleId><ArticleId IdType="pubmed">10689049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Bigio EH, Ince PG, et al. . Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations. Ann Neurol 2007;61:427&#x2013;34. 10.1002/ana.21147</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21147</ArticleId><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. . Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science 2006;314:130&#x2013;3. 10.1126/science.1134108</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. The molecular links between TDP-43 dysfunction and neurodegeneration. Adv Genet 2009;66:1&#x2013;34. 10.1016/S0065-2660(09)66001-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0065-2660(09)66001-6</ArticleId><ArticleId IdType="pubmed">19737636</ArticleId></ArticleIdList></Reference><Reference><Citation>Henstridge CM, Sideris DI, Carroll E, et al. . Synapse loss in the prefrontal cortex is associated with cognitive decline in amyotrophic lateral sclerosis. Acta Neuropathol 2018;135:213&#x2013;26. 10.1007/s00401-017-1797-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1797-4</ArticleId><ArticleId IdType="pmc">PMC5773656</ArticleId><ArticleId IdType="pubmed">29273900</ArticleId></ArticleIdList></Reference><Reference><Citation>Geser F, Brandmeir NJ, Kwong LK, et al. . Evidence of multisystem disorder in whole-brain map of pathological TDP-43 in amyotrophic lateral sclerosis. Arch Neurol 2008;65:636&#x2013;41. 10.1001/archneur.65.5.636</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.65.5.636</ArticleId><ArticleId IdType="pubmed">18474740</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, et al. . Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol 2013;74:20&#x2013;38. 10.1002/ana.23937</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23937</ArticleId><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Prudlo J, K&#xf6;nig J, Schuster C, et al. . Tdp-43 pathology and cognition in ALS: a prospective clinicopathologic correlation study. Neurology 2016;87:1019-23 10.1212/WNL.0000000000003062</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000003062</ArticleId><ArticleId IdType="pubmed">27488596</ArticleId></ArticleIdList></Reference><Reference><Citation>Cykowski MD, Powell SZ, Peterson LE, et al. . Clinical significance of TDP-43 neuropathology in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol 2017;76:402&#x2013;13. 10.1093/jnen/nlx025</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/nlx025</ArticleId><ArticleId IdType="pmc">PMC5901081</ArticleId><ArticleId IdType="pubmed">28521037</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, et al. . Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener 2014;15:9&#x2013;14. 10.3109/21678421.2013.805784</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.805784</ArticleId><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al. . Validation of the Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS): a cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:172&#x2013;9. 10.3109/21678421.2015.1030430</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1030430</ArticleId><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Siciliano M, Trojano L, Trojsi F, et al. . Edinburgh Cognitive and Behavioural ALS Screen (ECAS)-Italian version: regression based norms and equivalent scores. Neurol Sci 2017;38:1059&#x2013;68. 10.1007/s10072-017-2919-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-017-2919-4</ArticleId><ArticleId IdType="pubmed">28332040</ArticleId></ArticleIdList></Reference><Reference><Citation>Ye S, Ji Y, Li C, et al. . The Edinburgh cognitive and behavioural ALS screen in a Chinese amyotrophic lateral sclerosis population. PLoS One 2016;11:e0155496 10.1371/journal.pone.0155496</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0155496</ArticleId><ArticleId IdType="pmc">PMC4873026</ArticleId><ArticleId IdType="pubmed">27195772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora JS, Salas T, Camino Fernandez M, et al. . Spanish adaptation of the Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen (ECAS). Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 2017;16:1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">29212378</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto-Grau M, Burke T, Lonergan K, et al. . Screening for cognitive dysfunction in ALS: validation of the Edinburgh cognitive and behavioural ALS screen (ECAS) using age and education adjusted normative data. Amyotroph Lateral Scler Frontotemporal Degener 2017;18:99&#x2013;106. 10.1080/21678421.2016.1249887</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2016.1249887</ArticleId><ArticleId IdType="pubmed">27894201</ArticleId></ArticleIdList></Reference><Reference><Citation>Loose M, Burkhardt C, Aho-&#xd6;zhan H, et al. . Age and education-matched cut-off scores for the revised German/Swiss-German version of ECAS. Amyotroph Lateral Scler Frontotemporal Degener 2016;17:374&#x2013;6. 10.3109/21678421.2016.1162814</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2016.1162814</ArticleId><ArticleId IdType="pubmed">27027323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lul&#xe9; D, Burkhardt C, Abdulla S, et al. . The Edinburgh cognitive and behavioural amyotrophic lateral sclerosis screen: a cross-sectional comparison of established screening tools in a German-Swiss population. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:16&#x2013;23. 10.3109/21678421.2014.959451</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959451</ArticleId><ArticleId IdType="pubmed">25292386</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Goldstein LH, Simmons A, et al. . Word retrieval in amyotrophic lateral sclerosis: a functional magnetic resonance imaging study. Brain 2004;127:1507&#x2013;17. 10.1093/brain/awh170</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awh170</ArticleId><ArticleId IdType="pubmed">15163610</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Goldstein LH, Simmons A, et al. . Functional magnetic resonance imaging of verbal fluency and confrontation naming using compressed image acquisition to permit overt responses. Hum Brain Mapp 2003;20, :29&#x2013;40. 10.1002/hbm.10126</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hbm.10126</ArticleId><ArticleId IdType="pmc">PMC6872028</ArticleId><ArticleId IdType="pubmed">12953304</ArticleId></ArticleIdList></Reference><Reference><Citation>Ardila A, Bernal B, Rosselli M. How localized are language brain areas? A review of Brodmann areas involvement in oral language. Arch Clin Neuropsychol 2016;31:112&#x2013;22. 10.1093/arclin/acv081</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/arclin/acv081</ArticleId><ArticleId IdType="pubmed">26663825</ArticleId></ArticleIdList></Reference><Reference><Citation>Black HA, Leighton DJ, Cleary EM, et al. . Genetic epidemiology of motor neuron disease-associated variants in the Scottish population. Neurobiol Aging 2017;51:178.e11&#x2013;178.e20. 10.1016/j.neurobiolaging.2016.12.013</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2016.12.013</ArticleId><ArticleId IdType="pmc">PMC5302213</ArticleId><ArticleId IdType="pubmed">28089114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gregory JM, Elliot E, McDade K, et al. . Neuronal clusterin expression is associated with cognitive protection in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol 2019. 10.1111/nan.12575. [Epub ahead of print: 6 Aug 2019].</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nan.12575</ArticleId><ArticleId IdType="pmc">PMC7318312</ArticleId><ArticleId IdType="pubmed">31386770</ArticleId></ArticleIdList></Reference><Reference><Citation>Wicks P, Abrahams S, Papps B, et al. . Sod1 and cognitive dysfunction in familial amyotrophic lateral sclerosis. J Neurol 2009;256:234&#x2013;41. 10.1007/s00415-009-0078-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-009-0078-0</ArticleId><ArticleId IdType="pubmed">19252762</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams SM, Khan G, Harris BT, et al. . TDP-43 protein variants as biomarkers in amyotrophic lateral sclerosis. BMC Neurosci 2017;18:20 10.1186/s12868-017-0334-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12868-017-0334-7</ArticleId><ArticleId IdType="pmc">PMC5264476</ArticleId><ArticleId IdType="pubmed">28122516</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, et al. . Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol 2014;127:423&#x2013;39. 10.1007/s00401-013-1238-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1238-y</ArticleId><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Gautam M, Jara JH, Kocak N, et al. . Mitochondria, ER, and nuclear membrane defects reveal early mechanisms for upper motor neuron vulnerability with respect to TDP-43 pathology. Acta Neuropathol 2019;137:47&#x2013;69. 10.1007/s00401-018-1934-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1934-8</ArticleId><ArticleId IdType="pmc">PMC6339587</ArticleId><ArticleId IdType="pubmed">30450515</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, Frick P, Neumann M. The neuropathology associated with repeat expansions in the C9orf72 gene. Acta Neuropathol 2014;127:347&#x2013;57. 10.1007/s00401-013-1232-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1232-4</ArticleId><ArticleId IdType="pubmed">24356984</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>